Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

10.1186/1475-2840-4-13

Saved in:

Bibliographic Details
Main Authors:	Keech, A.C, Scott, R., Best, J.
Other Authors:	SURGERY
Format:	Article
Published:	2020
Subjects:	antidiabetic agent fenofibrate high density lipoprotein high density lipoprotein cholesterol low density lipoprotein cholesterol peroxisome proliferator activated receptor agonist placebo triacylglycerol antilipemic agent apolipoprotein B cholesterol adult aged article clinical trial controlled clinical trial controlled study coronary risk double blind procedure drug mechanism female high risk patient human hypertension ischemic heart disease long term care major clinical study male metabolic syndrome X non insulin dependent diabetes mellitus obesity randomized controlled trial treatment outcome waist circumference Australia blood cardiovascular disease coronary artery disease diabetes mellitus Finland middle aged New Zealand Aged Apolipoproteins B Cardiovascular Diseases Cholesterol Cholesterol, HDL Cholesterol, LDL Coronary Disease Diabetes Complications Diabetes Mellitus, Type 2 Double-Blind Method Female Fenofibrate Humans Hypolipidemic Agents Male Middle Aged Obesity Placebos Triglycerides
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/178030
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-178030
record_format	dspace
spelling	sg-nus-scholar.10635-1780302024-04-25T02:38:09Z Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] Keech, A.C Scott, R. Best, J. SURGERY antidiabetic agent fenofibrate high density lipoprotein high density lipoprotein cholesterol low density lipoprotein cholesterol peroxisome proliferator activated receptor agonist placebo triacylglycerol antilipemic agent apolipoprotein B cholesterol fenofibrate high density lipoprotein cholesterol low density lipoprotein cholesterol triacylglycerol adult aged article clinical trial controlled clinical trial controlled study coronary risk double blind procedure drug mechanism female high risk patient human hypertension ischemic heart disease long term care major clinical study male metabolic syndrome X non insulin dependent diabetes mellitus obesity randomized controlled trial treatment outcome waist circumference Australia blood cardiovascular disease coronary artery disease diabetes mellitus Finland middle aged New Zealand non insulin dependent diabetes mellitus obesity Aged Apolipoproteins B Australia Cardiovascular Diseases Cholesterol Cholesterol, HDL Cholesterol, LDL Coronary Disease Diabetes Complications Diabetes Mellitus, Type 2 Double-Blind Method Female Fenofibrate Finland Humans Hypolipidemic Agents Male Middle Aged New Zealand Obesity Placebos Triglycerides 10.1186/1475-2840-4-13 Cardiovascular Diabetology 4 13 2020-10-20T04:52:51Z 2020-10-20T04:52:51Z 2005 Article Keech, A.C, Scott, R., Best, J. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]. Cardiovascular Diabetology 4 : 13. ScholarBank@NUS Repository. https://doi.org/10.1186/1475-2840-4-13 14752840 https://scholarbank.nus.edu.sg/handle/10635/178030 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Unpaywall 20201031
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
topic	antidiabetic agent fenofibrate high density lipoprotein high density lipoprotein cholesterol low density lipoprotein cholesterol peroxisome proliferator activated receptor agonist placebo triacylglycerol antilipemic agent apolipoprotein B cholesterol fenofibrate high density lipoprotein cholesterol low density lipoprotein cholesterol triacylglycerol adult aged article clinical trial controlled clinical trial controlled study coronary risk double blind procedure drug mechanism female high risk patient human hypertension ischemic heart disease long term care major clinical study male metabolic syndrome X non insulin dependent diabetes mellitus obesity randomized controlled trial treatment outcome waist circumference Australia blood cardiovascular disease coronary artery disease diabetes mellitus Finland middle aged New Zealand non insulin dependent diabetes mellitus obesity Aged Apolipoproteins B Australia Cardiovascular Diseases Cholesterol Cholesterol, HDL Cholesterol, LDL Coronary Disease Diabetes Complications Diabetes Mellitus, Type 2 Double-Blind Method Female Fenofibrate Finland Humans Hypolipidemic Agents Male Middle Aged New Zealand Obesity Placebos Triglycerides
spellingShingle	antidiabetic agent fenofibrate high density lipoprotein high density lipoprotein cholesterol low density lipoprotein cholesterol peroxisome proliferator activated receptor agonist placebo triacylglycerol antilipemic agent apolipoprotein B cholesterol fenofibrate high density lipoprotein cholesterol low density lipoprotein cholesterol triacylglycerol adult aged article clinical trial controlled clinical trial controlled study coronary risk double blind procedure drug mechanism female high risk patient human hypertension ischemic heart disease long term care major clinical study male metabolic syndrome X non insulin dependent diabetes mellitus obesity randomized controlled trial treatment outcome waist circumference Australia blood cardiovascular disease coronary artery disease diabetes mellitus Finland middle aged New Zealand non insulin dependent diabetes mellitus obesity Aged Apolipoproteins B Australia Cardiovascular Diseases Cholesterol Cholesterol, HDL Cholesterol, LDL Coronary Disease Diabetes Complications Diabetes Mellitus, Type 2 Double-Blind Method Female Fenofibrate Finland Humans Hypolipidemic Agents Male Middle Aged New Zealand Obesity Placebos Triglycerides Keech, A.C Scott, R. Best, J. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
description	10.1186/1475-2840-4-13
author2	SURGERY
author_facet	SURGERY Keech, A.C Scott, R. Best, J.
format	Article
author	Keech, A.C Scott, R. Best, J.
author_sort	Keech, A.C
title	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
title_short	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
title_full	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
title_fullStr	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
title_full_unstemmed	Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
title_sort	fenofibrate intervention and event lowering in diabetes (field) study: baseline characteristics and short-term effects of fenofibrate [isrctn64783481]
publishDate	2020
url	https://scholarbank.nus.edu.sg/handle/10635/178030
_version_	1800914471704592384

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: Baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Similar Items